natgillin/translations-raw huggingface dataset:
Post-eksponeringsprofylakse: Alvorlig hepatotoksicitet, inkl. leversvigt påkrævende transplantation, er blevet rapporteret hos ikke hiv-smittede personer, som fik multiple doser af nevirapin i forbindelse med post-eksponeringsprofylakse (PEP), en ikke godkendt anvendelse.
Post-Exposure-Prophylaxis: Serious hepatotoxicity, including liver failure requiring transplantation, has been reported in HIV-uninfected individuals receiving multiple doses of nevirapine in the setting of post-exposure-prophylaxis (PEP), an unapproved use.
Post-hoc effektanalyse hos patienter med forsat stort eller meget stort alkoholforbrug ved randomisering
Post-hoc efficacy analysis in patients who maintained a high or very high DRL at randomisation
Post-hoc eksplorativ analyse med
Post-hoc exploratory analysis
Post-hoc- analyse af data fra de to kliniske fase 3 studier viste imidlertid, at regadenosons farmakokinetik ikke var påvirket i en lille undergruppe af patienter med laboratorieværdier, som tyder på nedsat leverfunktion (2,5 gange forhøjet transaminase eller 1,5 gange forhøjet serum-bilirubin eller protrombintid).
However, post- hoc analysis of data from the two Phase 3 clinical trials showed that the pharmacokinetics of regadenoson were not affected in a small subset of patients with laboratory values suggestive of impaired hepatic function (2.5-fold transaminase elevation or 1.5-fold elevation of serum bilirubin or prothrombin time).
Post-klimakterielle kvinder
Postmenopausal women
Post-markedsførings- og kompliansvurdering (som relevant i den pågældende medlemsstat)
Post-marketing and compliance assessment (as applicable to a Member State)
Post-marketing data omfatter isolerede tilfælde af overdosis, hvor den største daglige dosis af levodopa og entacapon har været henholdsvis 10.000 mg og 40.000 mg.
The post-marketing data includes isolated cases of overdose in which the reported highest daily doses of levodopa and entacapone have been at least 10,000 mg and 40,000 mg, respectively.
Post-marketing erfaring med sæsonbetinget T/LAIV
Post-marketing experience with seasonal T/LAIV
Post-marketing erfaring viser, at bivirkninger, herunder hypoglykæmi, er rapporteret i sjældne tilfælde (>1/10.000<1/1.000).
Based on post-marketing experience adverse drug reactions including hypoglycaemia have been reported rarely (>1/10,000
Post-marketing overvågning a) Før markedsføring i noget land i EU, vil Indehaveren af markedsføringstilladelsen have et post-marketing overvågningssystem på plads for at indsamle følgende oplysninger om patienter med medfødt AT-mangel, som behandles med ATryn
Post-marketing surveillance a) Prior to launch in any EU Member State, the MAH will set up a post-marketing surveillance programme to collect the following information about congenital AT deficient patients treated with ATryn
Post-marketing rapporter fra et andet lægemiddel i samme terapeutiske klasse
Post-marketing reports of another medicinal product of this class
Post-marketing rapporter: Systemisk hypersensitivitet omfatter symptomer så som anafylaksi, generaliseret urticaria, angioødem og dyspnø.
Post-marketing reports: Systemic hypersensitivity included symptoms such as anaphylaxis, generalized urticaria, angioedema and dyspnoea.
Post-marketing sikkerhedsovervågningsstudie
Post-Marketing Observational Safety Surveillance Study
Post-marketing-data
Post-marketing data
Post-operativ smerte og inflammation efter kirurgiske indgreb:
Post-operative pain and inflammation following surgical procedures:
Post-operative smerter: enkelt subcutan injektion.
Post-operative pain: single subcutaneous injection.
Post-operative sår-infektioner (svære og/eller alvorlige): 1,7 % versus 3,0 % i henholdsvis den intravenøse formulering og den subkutane formulering.
Post-operative wound infections (severe and/or serious): 1.7 % versus 3.0 % for the intravenous formulation versus subcutaneous formulation, respectively;
Post-transplantation lymfoproliferativ sygdom (forhøjet antal hvide blodlegemer i blodet efter en transplantation
Post-transplantation lymphoproliferative disorder (increase in the number of white blood cells in the blood after a transplantation)
Post-transplantation lymfoproliferativ sygdom (PTLD)
Post-transplant lymphoproliferative disorder (PTLD)
Post-traumatisk smerte
Post-traumatic pain
Postbus 552.
Postbus 552,
Postdosis dal FEV1 (mindste kvadraters gennemsnit) ved dag 1 og uge 26 (primært endepunkt)
Post-dose trough FEV1 (least squares mean) at day 1 and week 26 (primary endpoint)
Poster om rekonstitution
Reconstitution poster
Poster til apoteker/diabetes-klinikker skal indeholde følgende nøglelementer:
The Poster for pharmacies/diabetic units shall contain the following key elements:
Poster til fremvisning i apoteker/diabetes-klinikker
Poster for display in pharmacies/diabetic units;
Posteren om rekonstitution skal indeholde følgende hovedpunkter: at kravene til rekonstitution af Bortezomib SUN 3,5 mg er forskellige ved i.v. og s.c. anvendelse
The Reconstitution poster shall contain the following key elements: different reconstitution requirements for Bortezomib SUN 3.5 mg IV or SC use
Posteren om rekonstitution skal indeholde følgende hovedpunkter: at kravene til rekonstitution af VELCADE 3,5 mg er forskellige ved i.v. og s.c. anvendelse
The Reconstitution poster shall contain the following key elements: different reconstitution requirements for VELCADE 3.5 mg IV or SC use
Posterior cingulum og precuneus (pc, sagittalt snit)
Posterior cingulate and precuneus (pc, sagittal review)
Posterior reversibel encefalopati / Reversibel posterior leukoencefalopati- syndrom †
Posterior reversible encephalopathy / Reversible posterior leukoencephalopathy syndrome
Posterior reversibel encefalopatisyndrom (PRES)
Posterior Reversible Encephalopathy Syndrome (PRES)
Posterior reversibel encefalopatisyndrom (PRES) / Reversibel posterior leukoencefalopati-syndrom (RPLS)
Posterior reversible encephalopathy syndrome (PRES) / Reversible posterior leukoencephalopathy syndrome (RPLS)
Posterior reversibelt encefalopatisk syndrome
Posterior reversible encephalopathy syndromee
Posterior reversibelt encefalopatisyndrom (PRES)
Posterior reversible encephalopathy syndrome (PRES)
Posterior reversibelt encefalopatisyndrom (PRES) (også kaldet reversibelt posterior leukoencefalopati-syndrom (RPLS))
Posterior reversible encephalopathy syndrome (PRES) (also known as reversible posterior leukoencephalopathy syndrome (RPLS))
Posterior reversibelt encepalopati-syndrom (PRES)
Posterior reversible encephalopathy syndrome (PRES)
Posteriormente se puede volver a aumentar bajo estricto control hematológico.
The dose of Siklos may then be increased again under close haematological monitoring.
Posteriort
Posterior
Posteriort reversibelt encefalopati- syndrom
Alveolar proteinosis
Posteriort reversibelt encefalopati- syndrom*
Posterior reversible encephalopathy syndrome
Posteriort reversibelt encefalopati-syndrom (PRES)
Posterior Reversible Encephalopathy Syndrome (PRES)
Posteriort reversibelt encefalopatisk syndrom (PRES)
Posterior Reversible Encephalopathy Syndrome (PRES)
Posteriort reversibelt encefalopatisk syndrom, PRES (= reversibelt posteriort leukoencefalopatisk syndrom, RPLS)
Posterior reversible encephalopathy syndrome, PRES (Reversible posterior leukoencephalopathy syndrome-RPLS)
Posteriort reversibelt encefalopatisyndr om Monoparese Transitorisk iskæmisk anfald
Posterior reversible encephalopathy syndrome Monoparesis Transient ischaemic attack
posteriort reversibelt encefalopatisyndrom (PRES), en alvorlig nervesygdom med følgende symptomer: hovedpine, kvalme, opkastning, forvirring, krampeanfald og synstab.
Posterior reversible encephalopathy syndrome (PRES), a serious nervous system syndrome that has the following symptoms: headache, nausea, vomiting, confusion, seizures, and visual loss.
Posteriort reversibelt endocefalopati-syndrom (PRES)
Posterior reversible encephalopathy syndrome (PRES)
Posteriort reversibelt leukoencefalop ati-syndrom (PRES)
Posterior reversible encephalopathy syndrome (PRES)
Posteriort reversibelt leukoencefalopatisk syndrom (PRES)
Posterior reversible encephalopathy syndrome (PRES)
Postinjektionssyndrom
Post-injection syndrome
Postmarketing overvågning: Nervesystemet
Nervous system disorders:
Postmarketing-erfaring har vist, at de alvorligste bivirkninger er Stevens-Johnsons syndrom/toksisk epidermal nekrolyse, alvorlig hepatitis/leversvigt og lægemiddelreaktion med eosinofili og systemiske symptomer, kendetegnet ved udslæt med konstitutionelle symptomer, såsom feber, artralgi, myalgi, lympadenopati samt organpåvirkning, såsom hepatitis, eosinofili, granulocytopeni og nedsat nyrefunktion.
The postmarketing experience has shown that the most serious adverse reactions are Stevens-Johnson syndrome/ toxic epidermal necrolysis, serious hepatitis/hepatic failure, and drug reaction with eosinophilia and systemic symptoms, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lymphadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction.
Postmarketing-erfaring har vist, at de alvorligste bivirkninger er Stevens-Johnsons syndrom/toksisk epidermal nekrolyse, alvorlig hepatitis/leversvigt, og lægemiddelreaktion med eosinofili og systemiske symptomer, karakteriseret ved udslæt med symptomer, såsom feber, artralgi, myalgi, lymfadenopati samt organpåvirkning, såsom hepatitis, eosinofili, granulocytopeni og nedsat nyrefunktion.
The nevirapine postmarketing experience has shown that the most serious adverse reactions are Stevens-Johnson syndrome/toxic epidermal necrolysis, serious hepatitis/hepatic failure, and drug reaction with eosinophilia and systemic symptoms, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lymphadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction.
Postmarketing-erfaring har vist, at de alvorligste bivirkninger er Stevens-Johnsons syndrom/toksisk epidermal nekrolyse, alvorlig hepatitis/leversvigt, og lægemiddelreaktion med eosinofili og systemiske symptomer, karakteriseret ved udslæt med symptomer, såsom feber, artralgi, myalgi, lympadenopati samt organpåvirkning, såsom hepatitis, eosinofili, granulocytopeni og nedsat nyrefunktion.
The postmarketing experience has shown that the most serious adverse reactions are Stevens-Johnson syndrome/ toxic epidermal necrolysis, serious hepatitis/hepatic failure, and drug reaction with eosinophilia and systemic symptoms, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lymphadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction.
Postmarketingerfaringerne udgør i dag mere end 70.000 solgte hætteglas med 2 rapporter om selvbegrænsende allergiske reaktioner.
Post-marketing experience currently comprises greater than 70,000 vials sold, with two reports of self- limiting allergic reactions.
Postmenopausal osteoporose:
Postmenopausal osteoporosis
Postmenopausale kvinder
Post-menopausal women
Postmenopausale kvinder med intakt uterus
Postmenopausal women with a uterus
postnasalt dryp (for meget slim)
postnasal drip (excessive mucus)
Postnasalt dryp, sinussmerter, hvæsen
Postnasal drip, sinus pain, wheezing
Postoperativ blødning
Post-procedural haemorrhage
Postoperativ CSF-lækage forekom inden for 30 dage efter behandlingen hos 4/89 (4,5 %) forsøgspersoner behandlet med EVICEL (to tilfælde af CSF-lækage med nedsat sårheling og to tilfælde af rinoré) og hos 1/50 (2,0 %) forsøgspersoner behandlet med yderligere suturer.
Post-operative CSF leakage occurred within 30 days from treatment in 4/89 (4.5%) subjects treated with EVICEL (two cases of CSF leakage with impaired wound healing and two cases of rhinorrhoea) and in 1/50 (2.0%) subjects treated with additional sutures.
Postoperativ hæmothorax Hæmopericardium Intrakraniel blødning
Postoperative haemothorax Haemopericardium Intracranial bleeding
Postoperativ infektion
Postoperative infection
postoperativ smerte
post-operative pain
Postoperativ smerte blev evalueret ved hjælp af en selvadministreret 0- 100 mm visuel analog skala (VAS).
Postoperative pain was evaluated by a self-administered 0-100 mm visual analogue scale (VAS).
Postoperativ smerte og betændelse efter kirurgiske indgreb:
Post-operative pain and inflammation following surgical procedures:
Postoperativ smerte og inflammation efter kirurgiske indgreb
Post-operative pain and inflammation following surgical procedures:
Postoperative smerter og betændelse efter kirurgiske indgreb:
Post-operative pain and inflammation following surgical procedures:
Postoperative smerter og inflammation efter kirurgiske indgreb:
Post-operative pain and inflammation following surgical procedures:
postoperative sårkomplikationer (herunder blødning og infektion under eller efter operationen). øget mængde blodstørkningsproteiner (fibrinogen).
post-operative wound complications (including bleeding and infection during or after surgery). increased level of blood clotting proteins (fibrinogen).
postoperative,
operative
Postprandial glucosereduktion blev bekræftet i et delstudie ved en 4-timers standardiseret måltidstest hos patienter ukontrolleret på metformin alene eller i kombination med pioglitazon.
Postprandial glucose reduction was confirmed in a 4 hour standardised meal test sub-study in patients uncontrolled on metformin alone or in combination with pioglitazone.
Posttraumat isk smerte
Post- traumatic pain
Posttussiv opkastning
Post-tussive vomiting
Posttussiv opkastning Opkastning
Post-tussive vomiting Vomiting
Posttussiv opkastning1
Post-tussive vomiting1
Posttussiv opkastning1 Kraftig opkastning1
Post-tussive vomiting1 Retching1
postural
Vascular disorders
Postural hypotension, anfaldsvis ansigtsrødme
Postural hypotension, flushing
Postural svimmelhed*, synkope*
Dizziness postural*, Syncope
Potactasol 1 mg hætteglas skal opløses med 1,1 ml vand til injektionsvæsker.
Potactasol 1 mg vials must be reconstituted with 1.1 ml water for injections.
Potactasol 1 mg med 1.1 ml vand til injektioner (da det indeholder 10 % overskud)
Potactasol 1 mg with 1.1 ml water for injections (as it contains 10 % overage of fill)
Potactasol 1 mg pulver til koncentrat til infusionsvæske, opløsning
Potactasol 1 mg powder for concentrate for solution for infusion topotecan
Potactasol 4 mg hætteglas skal opløses med 4 ml vand til injektionsvæsker.
Potactasol 4 mg vials must be reconstituted with 4 ml water for injections.
Potactasol 4 mg med 4 ml vand til injektioner
Potactasol 4 mg with 4 ml water for injections
Potactasol 4 mg pulver til koncentrat til infusionsvæske, opløsning
Potactasol 4 mg powder for concentrate for solution for infusion topotecan
Potactasol Actavis 1 mg pulver til koncentrat til infusionsvæske, opløsning
Potactasol 1 mg powder for concentrate for solution for infusion
Potactasol Actavis 4 mg pulver til koncentrat til infusionsvæske, opløsning
Potactasol 4 mg powder for concentrate for solution for infusion
Potactasol bruges til at behandle:
Potactasol is used to treat:
Potactasol bør ikke anvendes til pædiatriske patienter, da erfaring med børn er begrænset (se pkt.
The experience in children is limited, therefore no recommendation for treatment of paediatric patients with Potactasol can be given (see sections 5.1 and 5.2).
Potactasol bør ikke anvendes til pædiatriske patienter, da erfaringen med børn er begrænset (se pkt.
The experience in children is limited, therefore no recommendation for treatment of paediatric patients with Potactasol can be given (see sections 5.1 and 5.2).
Potactasol er et "generisk lægemiddel".
Potactasol is a ‘generic medicine’.
Potactasol frarådes i tilfælde af alvorlig nedsat leverfunktion. hvis du har en lungebetændelse med tegn som hoste, feber og vejrtrækningsproblemer, se også punkt 4 ”Bivirkninger”.
Potactasol is not recommended in case of severe liver impairment; if you suffer from lung inflammation with signs such as cough, fever and difficulties in breathing, see also section 4 “Possible side effects”.
Potactasol frarådes, hvis din nyrefunktion er meget nedsat. hvis du har leverproblemer.
Potactasol is not recommended in case of severe kidney impairment; if you have liver problems.
Potactasol kan forringe din evne til at bekæmpe infektioner.
Potactasol may reduce your ability to fight infections.
Potactasol pulver til koncentrat for infusionsvæske, skal før infusion rekonstitueres med en passende mængde vand til injektioner, som følger:
Before infusion, Potactasol powder for concentrate for solution for infusion must be reconstituted with an appropriate volume of water for injections, as follows:
Potactasol udseende og pakningstørrelse
What Potactasol looks like and contents of the pack
Potensen (IE) er bestemt ved brug af chromogen assay i henhold til den Europæiske Farmakopé.
The potency (IU) is determined using the European Pharmacopoeia chromogenic assay.
Potensen (IE) er bestemt ved en 1-trins koagulationganalyse i henhold til FDA Mega-standard, som er kalibreret i henhold til WHO’s standard i Internationale Enheder (IE).
The potency (IU) is determined using the one-stage clotting assay against the FDA Mega standard which was calibrated against WHO standard in International Units (IU).
Potensen af bisphosphonat (højest for zoledronsyre), administrationsvej (se ovenfor) og kumulativ dosis
potency of the bisphosphonate (highest for zoledronic acid), route of administration (see above) and cumulative dose
potensproblemer
problems with erections
potent CYP3A4-hæmmer.
potent CYP3A4 inhibitor.
Potent4
Potent
Potente CYP 3A4-hæmmere: Itraconazol
Potent CYP 3A4 inhibitors: Itraconazole
Potente CYP 3A4-inducere såsom fenytoin, rifabutin, carbamazepin, barbiturater, rifampicin, prikbladet perikum og mindre potente inducere såsom de antiretrovirale lægemidler efavirenz og nevirapin kan forstærke den metaboliske clearance af cortisol, nedsætte den terminale halveringstid og dermed reducere de cirkulerende niveauer og øge variationerne af cortisolniveauerne (på grund af kortere terminal halveringstid).
Potent CYP 3A4 inducers such as phenytoin, rifabutin, carbamazepine, barbiturates, rifampicin, St John’s wort and less potent inducers such as the antiretroviral medicinal products efavirenz and nevirapine can enhance the metabolic clearance of cortisol, decrease terminal half-life and thus reduce circulating levels and increase fluctuations of cortisol (due to shorter terminal half-life).
Potente CYP- og transport-induktorer: Samtidig administration af gentagne doser (600 mg én gang dagligt i 22 dage) rifampicin (en CYP2B6-, 2C8-, 2C9-, 2C19- og 3A-induktor), samt en induktor af efflux- transporterne P-glykoprotein [P-gp] og brystcancer-resistent protein [BCRP] med teriflunomid (70 mg enkeltdosis) resulterede i et fald på cirka 40 % i teriflunomid-eksponeringen.
Potent cytochrome P450 (CYP) and transporter inducers: Co-administration of repeated doses (600 mg once daily for 22 days) of rifampicin (a CYP2B6, 2C8, 2C9, 2C19, 3A inducer), as well as an inducer of the efflux transporters P-glycoprotein [P-gp] and breast cancer resistant protein [BCRP] with teriflunomide (70 mg single dose) resulted in an approximately 40% decrease in teriflunomide exposure.
Potente CYP-enzyminhibitorer som f.eks. cimetidin og ketoconazol vil sandsynligvis ikke hæmme metaboliseringen af amifampridin via humane NAT'er og dermed forårsage en øget eksponering for amifampridin.
Potent cytochrome P450 (CYP450) enzyme inhibitors e.g. cimetidine, ketoconazole are not likely to inhibit the metabolism of amifampridine by human NATs giving rise to increased amifampridine exposure.
Potente CYP2D6-hæmmere eller potente CYP3A4- hæmmere
Strong CYP2D6 or strong CYP3A4 inhibitors
Potente CYP2D6-hæmmere og potente CYP3A4- hæmmere
Strong CYP2D6 and strong CYP3A4 inhibitors
Potente CYP3A-hæmmere inkluderer, men er ikke begrænset til, ritonavir, cobicistat, telaprevir, lopinavir, itraconazol, voriconazol, clarithromycin, telithromycin, posaconazol, nefazodon og grapefrugtjuice.
Strong CYP3A inhibitors include, but are not limited to ritonavir, cobicistat, telaprevir, lopinavir, itraconazole, voriconazole, clarithromycin, telithromycin, posaconazole, nefazodone and grapefruit juice.
Potente CYP3A-induktorer såsom carbamazepin, phenytoin og phenobarbital er kontraindiceret (se pkt.
Potent CYP3A inducers, such as carbamazepine, phenytoin and phenobarbital, are contraindicated (see section 4.3).
Potente CYP3A4-hæmmere (f.eks. itraconazol, ketoconazol, voriconazol, posaconazol, hiv- proteasehæmmere, clarithromycin, telithromycin, nefazodon)
Potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazol, posaconazol, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone)
Potente CYP3A4-hæmmere bør seponeres mindst 1 uge før initiering af ONIVYDE-behandlingen.
Strong CYP3A4 inhibitors should be discontinued at least 1 week prior to starting ONIVYDE therapy.
Potente CYP3A4-hæmmere.
Potent CYP3A4 inhibitors.
Potente CYP3A4-inducere
Potent CYP3A4 inducers
Potente CYP3A4-induktorer såsom rifampicin, phenobarbital, carbamazapin, phenytoin eller perikon bør ikke anvendes.
Potent CYP3A4 inducers such as rifampicin, phenobarbital, carbamazepine, phenytoin or St John’s Wort are not recommended.
Potente CYP3A4/PgP-hæmmere
Potent CYP3A4/PgP inhibitors
Potente hæmmere af CYP3A4 (f.eks. ketoconazol, indinavir, nelfinavir, ritonavir, saquinavir, clarithromycin, telithromycin, itraconazol, nefazodon og cobicistat) bør undgås.
Strong inhibitors of CYP3A4 (e.g., ketoconazole, indinavir, nelfinavir, ritonavir, saquinavir, clarithromycin, telithromycin, itraconazole, nefazodon and cobicistat) should be avoided.
Potente og moderate CYP3A4-induktorer
Potent and moderate CYP3A4 inducers
Potente P-glykoprotein (gp)-hæmmere
P-glycoprotein (P-gp) potent inhibitors
Potente P-gp-hæmmere
P-glycoprotein (P-gp) potent inhibitors
Potente P-gp-hæmmere (f.eks. ketoconazol, erythromycin og ciclosporin) kan, hvis de administreres sammen med Ofev, øge eksponeringen for nintedanib.
If co- administered with Ofev, potent P-gp inhibitors (e.g. ketoconazole, erythromycin or cyclosporine) may increase exposure to nintedanib.
Potente P-gp-induktorer (f.eks. rifampicin, carbamazepin, phenytoin og perikon) kan reducere eksponeringen for nintedanib.
Potent P-gp inducers (e.g. rifampicin, carbamazepine, phenytoin, and St. John’s Wort) may decrease exposure to nintedanib.
Potente P-gp-induktorer (f.eks. rifampicin, carbamazepin, phenytoin og prikbladet perikon) kan reducere eksponeringen for Vargatef.
Potent P-gp inducers (e.g. rifampicin, carbamazepine, phenytoin, and St. John’s Wort) may decrease exposure to nintedanib.
Potentiale for farmakodynamiske interaktioner med avanafil
Potential for pharmacodynamic interactions with avanafil
Potentiale for forstyrrelser i opioidmedieret analgesi
Potential for interference with opioid-mediated analgesia
Potentiale for hypersensitivitetsreaktioner eller anafylaktiske reaktioner
Potential for hypersensitivity or anaphylactic reactions
Potentiale for overfølsomhedsreaktioner og anafylaktiske reaktioner
Potential for hypersensitivity or anaphylactic reactions
Potentialet for andre lægemidlers påvirkning af Epclusa
Potential for other medicinal products to affect Epclusa
Potentialet for andre lægemidlers påvirkning af Harvoni
Potential for other medicinal products to affect Harvoni
Potentialet for interaktion mellem mepolizumab og et andet lægemiddel anses derfor for lav.
The potential for drug-drug interactions with mepolizumab is therefore considered low.
Potentialet for interaktioner mellem nintedanib og hormonale kontraceptiva er ikke undersøgt.
The potential for interactions of nintedanib with hormonal contraceptives was not explored.
Potentialet for krydsresistens mellem efavirenz og NRTI’ere er lille på grund af de forskellige bindingssteder på målet og virkningsmekanismen.
The potential for cross-resistance between efavirenz and NRTIs is low because of the different binding sites on the target and mechanism of action.